Century Therapeutics, Inc. · NASDAQ:IPSC
Century Therapeutics — Investor Presentation (May 2025)
39 slides from Century Therapeutics's investor presentation, May 15, 2025
Slide 1: May 2025 Corporate Overview
May 2025 Corporate Overview Exhibit 99.2
Slide 2: Forward-looking statements
2 Forward-looking statements This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historical facts
Slide 3: Clear focus on transformational value with unique iPSC-derived cell therapies
Estimated cash runway into 4Q26; re-allocating resources to enable key value milestones Enhanced preclinical pipeline and platform aiming to expand and multiply cell therapy value • Four potentially transformative programs engineered with industry-leading Allo-Evasion ed w on 5.0 • Leading programs
Slide 4: Clear differentiation from other allogeneic cell therapies with pathway to antibody-like scale
4 Clear differentiation from other allogeneic cell therapies with pathway to antibody-like scale Century’s ability to create multiple iPSC-derived cell types incorporating Allo-Evasion ability on stands apart from other allogeneic cell therapy approaches Engineerability • Control of differentiation
Slide 5: Allo-Evasion engineering aims to drive durable responses by enabling repeat dosing
5 Allo-Evasion engineering aims to drive durable responses by enabling repeat dosing for tighter control over drug exposure Clinical data from CNTY-101 in ELiPSE-1 show persistent exposure in the presence of an intact immune system1 With Allo-Evasion engineering Without Allo-Evasion eng n engineerin
Slide 6: Continued evolution to enhance holistic protection from major immunity pathways
6 Continued evolution to enhance holistic protection from major immunity pathways Century is a leader in immune evasion engineering Allo-Evasion 1.0 n Deletion of HLA-I o Deletion of HLA-II p Insertion of HLA-E Protection from: Native T-cells Native NK-cells Humoral immunity CNTY-101 1. Company data
Slide 7: The CD300a TASR ligand mimics natural signaling to provide broad protection from host NK cells
7 The CD300a TASR ligand mimics natural signaling to provide broad protection from host NK cells in preclinical studies CD300a detects disordered membrane lipids TASR mimics signaling of dead or dying cells Drug Product (live) Inhibit NK Cell TASR CD300a Dead/dying cell NK Cell Inhibit CD300a Male F
Slide 8: Century's T cells are protected from rejection in preclinical CDC, ADCC and ADCP assays
8 WT Gen 2.3 0 25 50 75 100 Antibody-Dependent Cellular Cytotoxicity Primary T cells (Donor 6705) + 1 ȝg ĮHLA-cI + Donor SC09 NK cells (2:1) % Survival ٓ GFP IdeStm 0 20 40 60 80 100 Complement Dependent Cytotoxicity Human Anti-HLA-ABC + 25% Complement (v/v) Donor SC07 Primary T Cells % Specific Lys
Slide 9: Century is advancing a focused iPSC pipeline across cell types and targets
9 Product Targets Indications Research IND-enabling Clinical Phase 1 Phase 2 Phase 3 CNTY-101 iNK (Allo-Evasion 1.0) CD19 B-cell-mediated autoimmune diseases CNTY-308 »¼iT (Allo-Evasion 5.0) CD19 B-cell-mediated autoimmune diseases B-cell malignancies CNTY-341 DE iT (Allo-Evasion 5.0) CD19 + CD22 B-
Slide 10: CNTY-101 CAR-iNK cell therapy with Allo-Evasion 1.0
CNTY-101 CAR-iNK cell therapy with Allo-Evasion 1.0
Slide 11: CNTY-101: A CD19-targeted CAR-iNK product candidate
11 Currently in Phase 1 in autoimmune disorders https://www.centurytx.com/wp-content/uploads/ASGCT24-CNTY-101-AI-Poster.pdf CNTY-101: A CD19-targeted CAR-iNK product candidate designed to provide precise control of drug exposure and enable repeat dosing CNTY-101 off-the-shelf CAR-iNK cell therapy ca
Slide 12: CNTY-101 is a differentiated autoimmune disease treatment
12 Allogeneic iPSC • Available ‘off-the-shelf’ • No patient apheresis required • No manufacturing wait time • Batch-to-batch consistency • Platform enables lower COGs than donor-derived or autologous NK cells • /MPPMRKTSXIRG]ǐTVMQEV]'%6-T) leads to deep B-cell depletion1 • Trafficking to secondary l
Slide 13: Autoimmune disorders present significant unmet medical need
13 Autoimmune disorders present significant unmet medical need Systemic Lupus Erythematosus (SLE) Lupus Nephritis (LN) Idiopathic Inflammatory Myopathy (IIM) Diffuse cutaneous Systemic Sclerosis (dcSSc) Characteristics Multiorgan, potentially fatal, inflammatory disease with risk for organ damage, i
Slide 14: Clear opportunity for allogeneic cell therapies in autoimmune indications
14 Clear opportunity for allogeneic cell therapies to address moderate to severe autoimmune indications by providing long-term, drug-free remission Significant patient population and unmet need • Tens of thousands of patients with unmet need in the US • Heterogeneous nature of patients with autoimmu
Slide 15: In vitro studies show CNTY-101 eliminates B cells with greater potency than primary CAR-T
15 In vitro studies show that CNTY-101 eliminates B cells with greater potency than primary CAR-T cells https://www.centurytx.com/wp-content/uploads/ASH_Chin_Natural-Killer-GD-Cells-Final.pdf Isolated B cells or CD19+ target cells were co-cultured with CNTY-101 or primary CAR-T at several E:Ts in 96
Slide 16: CALiPSO-1 Phase 1 study of CNTY-101 in refractory autoimmune diseases
16 CALiPSO-1 is a Phase 1 study of CNTY-101 underway in refractory B cell-mediated autoimmune diseases (NCT06255028) infusions in outpatient setting Inclusion: • Participants with moderate to severe SLE, LN, IIM, or dcSSc with treatment-resistant and active disease, after 2+ standard immunosuppressi
Slide 17: CNTY-101 ELiPSE-1 first-in-human study in relapsed/refractory B-cell lymphoma
17 CNTY-101 ELiPSE-1 first-in-human study: Initial clinical experience in relapsed/refractory B-cell lymphoma validates Century’s IPSC platform Heavily pre-treated patient population (n=23 safety; n=22 efficacy) • Median 4 prior lines (range 2-6); 48% (11/23) of patients received prior CART Favorabl
Slide 18: ELiPSE-1 is a dose-escalating Phase 1 study of CNTY-101 in B-cell malignancies
18 1. Standard lymphodepletion regimen: Fludarabine (30 mg/c/d) and cyclophosphamide IV (300 mg/m/d) for 3 days 2. Subjects who are assessed as stable disease or better may receive additional cycles of CNTY-101 3. Subjects at DL4A did not receive IL-2 on the day of CNTY-101 infusion but did receive
Slide 19: CNTY-101 exposure increased with dose, sustained at CALiPSO-1 doses
19 Source: Company data available as of March 7, 2025 CNTY-101 exposure increased with dose, sustained exposure at doses intended for CALiPSO-1 study Error bars show mean ± SD on original scale, subsequently log10 transformed. Due to log scale, low values are truncated at 1. All schedule B LDC+ cycl
Slide 20: CNTY-101 infusions showed similar exposure in presence or absence of endogenous lymphocytes
20 Infusion LDC • Lymphodepleting Chemotherapy (LDC) depleted patient NK/T cell counts and drove a transient spike of IL-15 cytokine • By post-infusion day 8, NK/T cell counts, IL-15 concentration returned to screening level • Similar PK profile observed for each CNTY-101 infusion within a cycle des
Slide 21: CNTY-101 cells detected in lymph node tumor biopsies
21 Source: Company data as of March 7, 2025 CNTY-101 cells were detected in lymph node tumor biopsies early post-treatment in Dose Level 3B and 4B CNTY-101 iNK cells traffic to lymph nodes, observed more frequently at higher doses CARTNFAIFNG CARTNFAIFNG CAR CAR Baseline Day 10 CARTNFAIFNG Scale bar
Slide 22: CNTY-101 demonstrated deep B-cell depletion and naive re-emergent B-cell profile
22 CNTY-101 treatment demonstrated deep B-cell depletion and was associated with naive non-class switched profile of re-emergent B-cells Data in r/r NHL patients supports the application of CNTY-101 in autoimmune diseases B-cell depletion Re-emergent B-cell profile • Rapid and effective depletion of
Slide 23: CNTY-308 CD19 CAR-iT cell with Allo-Evasion 5.0
CNTY-308 '%6»¼-iT cell with Allo-Evasion 5.0
Slide 24: The current CAR-T cell therapy market represents ~$4.5B worldwide sales
24 CARVYKTI® ($963M) ABECMA® ($406M) YESCARTA® ($1570M) BREYANZI® ($747M) KYMRIAH® ($443M) TECARTUS® ($403M) 2024 Worldwide Sales1 $4.5B ƒ All currently marketed CAR-T cell therapies are patient-derived (‘primary’ or ‘autologous’) DE T cells delivered as a mixture of cells expressing CD4 or CD82 ƒ A
Slide 25: CNTY-308 is an iPSC-derived CD19-targeted CAR-iT for B-cell-mediated disease
25 CNTY-308 is an iPSC-derived CD19-targeted CAR-iT intended for B-cell-mediated disease 1. https://www.centurytx.com/wp-content/uploads/ASH_Heinze_iPSC-Derived-CD4-CD8-Final.pdf 2. Company data on file CD4+/CD8+ »¼ iT-cell • CD19-targeted CAR to target B-cells for cytotoxic depletion • 4-1BB and CD
Slide 26: Century's process is designed to control the ratio of CD4+ to CD8+
26 https://www.centurytx.com/wp-content/uploads/ASH_Heinze_iPSC-Derived-CD4-CD8-Final.pdf Century’s process is designed to control the ratio of CD4+ to CD8+ while I\TERHMRKHMJJIVIRXMEXMRKIRKMRIIVIH'%6M47'GIPPWXS»¼'%6-T cells Stage Expansion from iPSCs (-fold) Ending Viability 1 3 90% 2 54,000 48% 3+
Slide 27: Preclinical iPSC-derived CAR-T cells show characteristics similar to primary CAR-T cells
27 Function 1’ CAR-T CNTY-308 IL-2 secretion (pg/mL) ~3,000 ~2,000 Requires exogenous IL-2/IL-15 No No Repeat killing (rounds) > 10 > 10 Persistence in blood (days) 32 32 Tumor control after rechallenge (in vivo) Yes Yes CNTY-308 and 1’ CAR-T • Self-supports with own target-mediated IL-2 • High func
Slide 28: Century's iPSC-derived CAR-T cells display functional characteristics of adult primary T cells
28 Century’s iPSC-derived CAR-DET cells display the functional characteristics of adult primary T cells: In vitro activity Effective T cell therapies require the generation of iPSC-CAR-T cells with three key in vitro cell functions Eff ti T ll th i i th ti f iPSC CAR T ll Cytotoxicity: Effector func
Slide 29: Century iPSC-CAR-T cells showed comparable activity to primary CAR-T in animal studies
29 In preclinical animal studies, Century iPSC-CAR-T cells showed comparable activity to primary CAR-T cells Source: Company data Complete tumor control Measurable long-XIVQTIVWMWXIRGIǐmo Cytotoxicity maintained upon re-challenge with engrafted cells In vivo experimental details • Disseminated Nalm6
Slide 30: CNTY-341 is an iPSC-derived CD19/CD22 dual-targeted CAR-iT
30 CNTY-341 is an iPSC-derived CD19/CD22 dual-targeted CAR-iT intended for B-cell malignancies 1. https://doi.org/10.1182/blood.2021010930; https://doi.org/10.1038/s41571-023-00754-1 2. B-ALL: B-cell acute lymphoblastic leukemia; https://doi.org/10.2147/ITT.S288546; https://doi.org/10.1038/s41408-02
Slide 31: Century's solid tumor programs target validated targets with proprietary CARs
31 Century’s solid tumor programs target validated targets with proprietary CARs • »¼CAR iT cells • Includes Allo-Evasion 5.0 designed to evade host T-cell, NK-cell, and humoral immunity • Novel targeting approaches include • Proprietary nectin-4 CAR • Novel TCRs providing additional functions • Nov
Slide 32: Century Platform: iPSC cell foundry
a CENTURY Platform: iPSC cell foundry THERAPEUTICS
Slide 33: Century's robust pre-clinical pipeline addresses critical barriers confronting cellular therapies
33 Century’s robust pre-clinical pipeline has potential to address critical barriers confronting cellular therapies Multiple iPSC-derived immune effector cells iPSC-enabled engineering solutions iple iPSC-de Opportunity across PSC enabled multiple diseases portunity acr engineering solutions • Cytok
Slide 34: Century's capability to make multiple cell types enables optimal matching to indication
34 Adaptive lymphocytes – capable of generating distinct functional attributes Greatest proliferative potential – potentially most useful for ongoing antigenic pressure GvHD risk, eliminated by knockout of T cell receptor (TCR) Potential for long-lived memory, mediating immune surveillance Bridge be
Slide 35: Precision CRISPR MAD7-mediated sequential gene editing of iPSCs
35 Precision CRISPR MAD7-mediated sequential gene editing of iPSCs generates uniform product candidates Multiple gene edits (KO/KI) iPSC Engineered iPSC Master Cell Bank (MCB) Sequential selection steps iPSC Precision Engineering CRISPR-mediated HDR (MAD 7) Advantages of Century’s Platform Precise C
Slide 36: Century platform and in-house manufacturing: Pathway to scalable, profitable cell therapy
36 Century platform and in-house manufacturing: Pathway to scalable, profitable cell therapy Established in-house manufacturing from development to launch Quality product at disruptive scale and cost of goods • Built-for-purpose 53,000 ft2 cGMP facility • Key leaders each with 1–2 decades of cell th
Slide 37: Manufacturing development shows progress in scalable cell production systems
37 https://www.centurytx.com/wp-content/uploads/ACS-Spring-2025-Scaleable-bioreactors.pdf Century’s manufacturing development shows progress in scalable, dynamic cell production systems towards antibody-like cost and scale 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Viable Cell Concentration Culture Day iNK
Slide 38: Clear focus on transformational value with unique iPSC-derived cell therapies
Estimated cash runway into 4Q26; re-allocating resources to enable key value milestones Enhanced preclinical pipeline and platform aiming to expand and multiply cell therapy value • Four potentially transformative programs engineered with industry-leading Allo-Evasion ed w on 5.0 • Leading programs
Slide 39: )) CENTURY
—= )) CENTURY yy THERAPEUTICS
Century Therapeutics — Investor Presentation (May 2025) on 6ix